

ProGenosis is a biotechnology company dedicated to the determination of **protein interactions** with a primary focus on receptor-ligand interactions.

Our proprietary technology platform is geared to develop efficient, innovative and convenient **Bifunctional Hybrid Proteins (BHPs)**, which can be used for protein domain studies.

ProGenosis provides Life Science companies with **R&D customized services** in its core business field.

ProGenosis has developed a BHP expression platform which uses a very robust and efficient positive drug-based screening system dedicated to the easy and straightforward selection of fully soluble and well-folded proteins.

What's the BHP technology ?

Scientists have always been dealing with quite complex proteins involved in intricate environment of interactions. These proteins are sometimes unavailable as functional and suitable material. Rather than using the whole protein of interest, the BHP technology allows the dissociation of the different structural elements of a protein. In this way, the **protein-protein interaction** environment is **simplified** and brought into an easily-manageable unit, the **BHP**, for **use in protein domain studies**. Our technologies have been validated by multiple research projects related to industrial final products.

What can ProGenosis technology be used for ?

ANTIBODY DEVELOPMENT

- Display of cryptic regions
- Display of non-immunodominant regions
- Sub-unitary vaccines

ANTIBODY CHARACTERISATION

- Epitope mapping (linear and non-linear)
- Key amino-acid determination
- Titration assay, ELISA, dissociation constant

PROTEIN EXPRESSION

- Difficult to express protein
- Extracellular protein domain
- Extracellular loops of GPCR, ion channel,...



How to contact us ?

ProGenosis s.a. – Tour 5 GIGA, B34, niveau +3, Avenue de l'Hôpital 11, 4000 Liège Belgium - Phone : + 32 4 361 33 29 - Fax : + 32 4 361 12 61 - www.progenosis.com

Dr N. Ruth, Business Development Assistant Director, nruth@progenosis.com